Hannum E, Liu X, Wang F. Estimating the effects of educational system contraction: the case of China's rural school merger initiative. Econ Dev Cult Change. 2021 Oct 1;70(1):485-528. doi: 10.1086/711654
Frick A, Benton C, Suzuki O, Dong O, Howard R, El-Sabae H, Wiltshire T. Implementing clinical pharmacogenomics in the classroom: student pharmacist impressions of an educational intervention including personal genotyping. Pharmacy (Basel). 2018 Oct 23;6(4):115. doi: 10.3390/pharmacy6040115
Barnett CL, Davenport MS, Montgomery JS, Wei JT, Montie JE, Denton BT. Cost‐effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer. BJU Int. 2018 Jul;122(1):50-8.
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Dickinson KL, Patil SR, Pattanayak SK, Poulos C, Yang JH. Nature's call: impacts of sanitation choices in Orissa, India. Econ Dev Cult Change. 2015 Oct;64(1):1-29.
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0